RT Journal Article
SR Electronic
T1 Carbon Ion Radiotherapy <em>Versus</em> Perioperative Adjuvant Chemotherapy and Curative Surgery for Resectable Pancreatic Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 809
OP 815
DO 10.21873/anticanres.16222
VO 43
IS 2
A1 YAMAMOTO, NAOTO
A1 OSHIMA, TAKASHI
A1 KAWAHARA, SHINNOSUKE
A1 TAKAHASHI, DAISHI
A1 KAMIOKA, YUTO
A1 MURAKAWA, MASAAKI
A1 KATOH, HIROYUKI
A1 UENO, MAKOTO
A1 MORINAGA, SOICHIRO
YR 2023
UL http://ar.iiarjournals.org/content/43/2/809.abstract
AB Background/Aim: The standard treatment for resectable pancreatic cancer is preoperative adjuvant chemotherapy (NAC) + curative surgery + adjuvant chemotherapy. Although excellent local control results of carbon ion radiotherapy (CIRT) for pancreatic cancer have been reported, no reports have compared CIRT with the standard treatment for resectable pancreatic cancer. In this study, we compared the results of CIRT for resectable pancreatic cancer with those of standard therapy and investigated the usefulness of CIRT. Patients and Methods: The subjects were 35 patients who underwent CIRT for clinical cT1-2, N0-1, and M0 cancers at Kanagawa Cancer Center, Yokohama, Japan, from September 2018 to September 2021, and 110 patients who underwent standard treatment (NAC + curative surgery + adjuvant). Overall survival (OS) and recurrence-free survival (PFS) were compared between the two groups using propensity score-matching (PSM). Results: Twenty-three CIRT monotherapy patients were matched with NAC + curative surgery + adjuvant chemotherapy patients by PSM. Although there was no significant difference in RFS between the two groups, OS was significantly poorer in the CIRT monotherapy group than in the NAC + curative surgery + adjuvant chemotherapy group. Conclusion: This single-centre retrospective propensity score-matched comparison of CIRT and NAC + curative resection + adjuvant chemotherapy as the standard therapy for resectable pancreatic cancer showed an inferiority of CIRT in terms of OS, but no difference in PFS. Therefore, CIRT monotherapy may be a treatment strategy for patients with contraindications for standard treatment of curative surgery plus perioperative chemotherapy.